Aptabio Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
41
- Stock Symbol
-
293780
- Investments
-
2
- Share Price
-
$3.37
- (As of Friday Closing)
Aptabio General Information
Description
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.
Contact Information
Website
www.aptabio.comCorporate Office
- Heungdeok IT Valley, 13
- Heungdeok 1-ro, Giheung-gu
- Yongin, Gyeonggi
- South Korea
Corporate Office
- Heungdeok IT Valley, 13
- Heungdeok 1-ro, Giheung-gu
- Yongin, Gyeonggi
- South Korea
Aptabio Stock Performance
As of 13-Nov-2026, Aptabio’s stock price is $3.37. Its current market cap is $94.6M with 28.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.37 | $3.49 | $2.50 - $7.40 | $94.6M | 28.1M | 61.7K | -$0.37 |
Aptabio Financials Summary
As of 30-Jun-2026, Aptabio has a trailing 12-month revenue of $3.28M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 81,224 | 167,309 | 90,346 | 117,880 |
| Revenue | 3,275 | 2,598 | 2,463 | 248 |
| EBITDA | (8,557) | (9,643) | (18,970) | (11,438) |
| Net Income | (10,246) | (11,486) | (21,531) | (9,225) |
| Total Assets | 35,253 | 41,685 | 52,570 | 71,794 |
| Total Debt | 3,184 | 3,071 | 5,106 | 10,813 |
Aptabio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aptabio Patents
Aptabio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026230945-A1 | Composition comprising pyrazole derivative for treating ocular diseases | Pending | 29-Apr-2025 | ||
| WO-2026221354-A1 | Pharmaceutical composition for preventing or treating bcl-2 family inhibitor-resistant acute myeloid leukemia | Pending | 16-Apr-2025 | ||
| WO-2026014993-A1 | Composition comprising pyrazole derivative for treating cancer | Pending | 12-Jul-2024 | ||
| EP-4501920-A1 | Novel pyrazole derivatives | Inactive | 31-Mar-2022 | ||
| JP-2025514621-A | Novel pyrazole derivatives | Inactive | 31-Mar-2022 | A61P35/00 |
Aptabio Signals
Aptabio Investments & Acquisitions (2)
Aptabio’s most recent deal was a Merger/Acquisition with likalika. The deal was made on 01-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| likalika | 01-Jan-2025 | Merger/Acquisition | Other Consumer Durables | ||
| FMW | 23-Jul-2024 | Corporate | Food Products |
Aptabio ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
41.27 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,669
Rank
Percentile
Pharmaceuticals
Industry
of 895
Rank
Percentile
Pharmaceuticals
Subindustry
of 431
Rank
Percentile
Aptabio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| likalika | Seoul, South Korea | 2019 |
Aptabio FAQs
-
When was Aptabio founded?
Aptabio was founded in 2009.
-
Where is Aptabio headquartered?
Aptabio is headquartered in Yongin, South Korea.
-
What is the size of Aptabio?
Aptabio has 41 total employees.
-
What industry is Aptabio in?
Aptabio’s primary industry is Pharmaceuticals.
-
Is Aptabio a private or public company?
Aptabio is a Public company.
-
What is Aptabio’s stock symbol?
The ticker symbol for Aptabio is 293780.
-
What is the current stock price of Aptabio?
As of 13-Nov-2026 the stock price of Aptabio is $3.37.
-
What is the current market cap of Aptabio?
The current market capitalization of Aptabio is $94.6M.
-
What is Aptabio’s current revenue?
The trailing twelve month revenue for Aptabio is $3.28M.
-
What is Aptabio’s annual earnings per share (EPS)?
Aptabio’s EPS for 12 months was -$0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process